obesity

Wegovy® 7.2 mg is already available in the European Union for adults with obesity through three separate 2.4 mg injections administered weekly.

The company’s presentations at EASL 2026 build on results from the Phase 3 ESSENCE programme, where semaglutide 2.4 mg previously demonstrated significant reductions in liver inflammation and fibrosis among patients with MASH.

The agreement excludes China, Hong Kong, Macau, and Taiwan, where SiranBio will retain rights.

The decision positions LANGLARA as only the fourth insulin glargine product available in the US market, joining established products commercialized by Novo Nordisk, Sanofi and Eli Lilly.

The study showed that oral semaglutide achieved a significantly greater reduction in HbA1c levels, a key marker of blood sugar control, compared to placebo.

The approval specifically applies to adults diagnosed with obesity and does not extend to individuals who are overweight with a BMI below 30kg/m² using Wegovy for weight management.

The collaboration leverages JW Pharmaceutical’s established research and development capabilities to accelerate the drug’s entry into South Korea’s growing metabolic disease sector.

Foundayo (orforglipron) is the first once-daily oral GLP-1 approved for weight management with no restrictions on food, water, or timing.

When combined with a reduced-calorie diet and regular physical activity, Foundayo helps patients shed excess weight and maintain their progress.

The drug works as a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, requiring no food or water restrictions before taking it.